<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.business-standard.com/article/pti-stories/aurobindo-pharma-gets-14-observations-from-the-usfda-for-hyderabad-plant-119111401744_1.html"/>
    <meta property="og:site_name" content="Business-Standard"/>
    <meta property="article:published_time" content="2019-11-14T14:50:00+00:00"/>
    <meta property="og:title" content="Aurobindo Pharma gets 14 observations from the USFDA for Hyderabad plant"/>
    <meta property="og:description" content="The observations issued by the USFDA notifies the company's management of objectionable conditions at the inspected facility"/>
  </head>
  <body>
    <article>
      <h1>Aurobindo Pharma gets 14 observations from the USFDA for Hyderabad plant</h1>
      <h2>The observations issued by the USFDA notifies the company's management of objectionable conditions at the inspected facility</h2>
      <address><time datetime="2019-11-14T14:50:00+00:00">14 Nov 2019, 14:50</time> by <a rel="author">Press Trust of India</a></address>
      <p><a href="https://www.business-standard.com/topic/aurobindo-pharma">Aurobindo Pharma </a>has received 14 observations from the US health regulator for its Hyderabad-based plant, according to a regulatory filing.</p>
      <p>The US Food and Drug Administration (USFDA) inspected company's Unit IV, a general injectable formulation manufacturing facility situated at Pashamylaram, Hyderabad from November 4-13, <a href="https://www.business-standard.com/topic/aurobindo-pharma">Aurobindo Pharma </a>said.</p>
      <p>"At the end of the inspection, we have been issued a Form 483 with 14 observations," it added.</p>
      <p>The company believes that none of the observations are related to data integrity issues and, it will respond to the <a href="https://www.business-standard.com/topic/usfda">USFDA </a>within the stipulated timeline, <a href="https://www.business-standard.com/topic/aurobindo-pharma">Aurobindo Pharma </a>said.</p>
      <p>The observations issued by the <a href="https://www.business-standard.com/topic/usfda">USFDA </a>notifies the company's management of objectionable conditions at the inspected facility.</p>
    </article>
  </body>
</html>